Horizon Therapeutics PLC $ 28.2 0.92 (3.35%)
Volume:
2,301,629
Avg Vol (1m):
1,332,785
Market Cap $:
5.26 Bil
Enterprise Value $:
5.75 Bil
P/E (TTM):
65.60
P/B:
3.45
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $28.2 | ||
Manual of Stocks™ Web
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.64 | ||
| Equity-to-Asset | 0.41 | ||
| Debt-to-Equity | 0.9 | ||
| Debt-to-EBITDA | 3.41 | ||
| Interest Coverage | 1.2 | ||
| Piotroski F-Score | 8 | ||
| Altman Z-Score | 1.64 | ||
| Beneish M-Score | -2.86 | ||
| WACC vs ROIC | |||
Profitability | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 10.29 | ||
| Net Margin % | 6.08 | ||
| ROE % | 6.66 | ||
| ROA % | 1.97 | ||
| ROC (Joel Greenblatt) % | 648.57 | ||
| 3-Year Revenue Growth Rate | 14.4 | ||
| 3-Year EBITDA Growth Rate | 11.5 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 65.6 | ||
| Forward PE Ratio | 15.95 | ||
| PE Ratio without NRI | 65.6 | ||
| Price-to-Owner-Earnings | 32.51 | ||
| PB Ratio | 3.45 | ||
| PS Ratio | 3.85 | ||
| Price-to-Free-Cash-Flow | 14.87 | ||
| Price-to-Operating-Cash-Flow | 14.39 | ||
| EV-to-EBIT | 43.55 | ||
| EV-to-EBITDA | 14.31 | ||
| EV-to-Revenue | 4.52 | ||
| Current Ratio | 2.2 | ||
| Quick Ratio | 2.12 | ||
| Days Inventory | 53.41 | ||
| Days Sales Outstanding | 112.48 | ||
| Days Payable | 40.62 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 1.29 | ||
| Price-to-Median-PS-Value | 1.06 | ||
| Earnings Yield (Greenblatt) % | 2.32 |